Omalizumab FDA Link

An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.

Also Known As:

Xolair; Immunoglobulin G, anti-(human immunoglobulin E Fc region)(human-mouse monoclonal E25 clone pSVIE26 gamma-chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 kappa-chain, dimer

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Omalizumab: 2445
        Anti-Idiotypic Antibodies: 1368
        Omalizumab: 2445
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Omalizumab: 2445
        Anti-Idiotypic Antibodies: 1368
        Omalizumab: 2445
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Omalizumab: 2445
        Anti-Idiotypic Antibodies: 1368
        Omalizumab: 2445

Minako Inazawa Selected Research

Minako Inazawa Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure